Sialic acid associated to VEGFR2 of the endothelial cell surface is implicated in VEGF-dependent angiogenesis by Rusnati, Marco et al.
Page 123
conferenceseries.com




September 17-19, 2018 | Rome, Italy
4th Glycobiology World Congress
Sialic acid associated to VEGFR2 of the endothelial cell surface is implicated in VEGF-dependent 
angiogenesis
Marco Rusnati1, Paola Chiodelli1, Giulia Paiardi1, Pasqualina D’ursi2, Alessandro Orro2, Matteo Uggeri2 and Paola Fossa3
1University of Brescia, Italy 
2Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (MI), Italy
3University of Genoa, Italy
Sialic acid (NeuAc) is a major anion on the endothelial cell (EC) where, by governing different molecular interactions it modulates important processes including angiogenesis. NeuAc is usually associated to N-glycan linked to various receptors, 
including the vascular endothelial growth factor receptor-2 (VEGFR2), the main pro-angiogenic receptor on ECs. By means 
of complementary approaches including computational analysis, surface plasmon resonance, immunoprecipitation, enzymatic 
digestion, immunofluorescence, cross-linking experiments with sugar-binding lectins and SiRNA targeting sialyltransferases 
(STs), we demonstrate that VEGFR2 bears both α,1-fucose and α(2,6)-linked sialic acid (NeuAc). However, only the latter is 
required for VEGF binding to VEGFR2 and consequent VEGF-dependent VEGFR2 activation and motogenic response in 
ECs. Accordingly, among the various lectin assayed, only the α(2-6)-NeuAc-binding lectin Sambucus nigra (SNA) prevents 
VEGF-dependent VEGFR2 autophosphorylation, EC motility, proliferation motogenesis. Also, it inhibits VEGF-dependent 
angiogenesis in the chick-embryo chorioallantoic membrane neovascularization assay and mouse matrigel plug assay in vivo. 
Interestingly, downregulation of ST6Gal-1 expression by siRNA transduction inhibits VEGFR2 α(2,6)-NeuAc sialylation that 
is paralleled by an increase of ST3Gal-1 expression that results in an ex-novo α(2,3)-NeuAc sialylation of the receptor that 
functionally rescues VEGF/VEGFR2 interaction. Since these data point to VEGFR2 sialylation as a target for the treatment 
of angiogenesis-dependent diseases, we have started an integrated approach made up of in silico, biochemical and biological 
methodologies to speed up the process of discovery of compounds able to bind the common structural framework involved in 
catalysis shared by the different STs implicated in the sialylation of VEGFR2, to be evaluated for their anti-angiogenic potential..
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